- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 7/62 - PolymyxinesPeptides apparentés
Détention brevets de la classe C07K 7/62
Brevets de cette classe: 129
Historique des publications depuis 10 ans
|
10
|
13
|
11
|
11
|
10
|
5
|
11
|
4
|
10
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Xellia Pharmaceuticals ApS | 93 |
10 |
| Spero Therapeutics, Inc. | 49 |
10 |
| Monash University | 727 |
8 |
| Northern Antibiotics Oy | 7 |
6 |
| MicuRx Pharmaceuticals, Inc. | 10 |
4 |
| New Pharma Licence Holdings Limited | 4 |
4 |
| Northern Antibiotics Ltd. | 6 |
4 |
| Shanghai Micurx Pharmaceutical Co., Ltd. | 20 |
4 |
| Cidara Therapeutics, Inc. | 72 |
3 |
| Universiteit leiden | 203 |
3 |
| Universitat de Barcelona | 301 |
3 |
| Spero Therapeutics, Inc. | 3 |
3 |
| The Regents of the University of California | 20574 |
2 |
| Board of Regents, The University of Texas System | 6050 |
2 |
| The Trustees of Columbia University in the City of New York | 3633 |
2 |
| Purdue Research Foundation | 3856 |
2 |
| Auckland UniServices Limited | 499 |
2 |
| Centauri Therapeutics Limited | 16 |
2 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 744 |
2 |
| Helperby Therapeutics Limited | 62 |
2 |
| Autres propriétaires | 51 |